Weigao Group 1066

Re: Weigao Group 1066

Postby winston » Tue Jan 08, 2013 2:52 pm

vested

CGC reduces stake in WEIGAO GROUP (01066.HK) to 11.3%

The Capital Group Companies (CGC), a US-based fund company, sold down its stake in WEIGAO GROUP (01066.HK) by 17.892 million shares on January 3 for nearly $139 million after cashing in more than $134 million in late December by disposing of certain shares, taking its interest down to 11.3% from 12.26%, stock exchange information shows.


Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 100357
Joined: Wed May 07, 2008 9:28 am

Re: Weigao Group 1066

Postby winston » Wed Mar 18, 2015 9:00 pm

not vested

WEIGAO GROUP annual net profit up 179.64% to RMB1.085B; final div 3.5 fen

WEIGAO GROUP (01066.HK) -0.080 (-1.322%) Short selling $1.34M; Ratio 2.243% announced that for the last year as of the end of December, the net profit rose 179.64% yearly to RMB1.085 billion.

The EPS equaled 24 fen; a final dividend of 3.5 fen was declared. The dividend equaled 3.1 fen in the year-ago period.

Meanwhile, the turnover rose 14.4% yearly to RMB5.278 billion.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 100357
Joined: Wed May 07, 2008 9:28 am

Re: Weigao Group 1066

Postby winston » Thu Sep 13, 2018 10:56 am

not vested

WEIGAO GROUP(1066)

Analysis:
At the beginning of the year, Shandong Weigao Group Medical Polymer (1066) optimized its product strategies, reclassified from former single-use consumables, hemodialysis business and orthopedic business into eight business segments, comprising clinical nursing care, wound management, blood management, pharma packaging, medical testing, anesthesia and surgical related products, orthopedics and interventional products.

These segments cover an enormous size of market.

For the six months ended 30 June 2018, the revenue of the Group was RMB4.15 billion, representing an increase of 3 9.4% over the same period last year.

Turnover of high value-added products (with a gross profit margin of over 60%) accounted for 61.7% (same period last year: 57.9%) of the total turnover.

Excluding extraordinary items, net profit attributable to shareholders was RMB762 million, representing an increase of 17.2% when compared with the same period last year. (I do not hold the above stock)

Strategy:
Buy-in Price: $7.30, Target Price: $8.00, Cut Loss Price: $6.90

Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 100357
Joined: Wed May 07, 2008 9:28 am

Previous

Return to S to Z

Who is online

Users browsing this forum: No registered users and 2 guests